Gene secrets could improve lung cancer drug safety
NCT ID NCT05987956
First seen Apr 06, 2026 · Last updated May 24, 2026 · Updated 5 times
Summary
This study looks at how tiny genetic differences (called SNPs) in ALK and CYP3A4 genes influence how well the drug alectinib works and what side effects it causes in people with ALK-positive non-small cell lung cancer. Researchers will collect blood samples from 600 patients and use precise DNA sequencing to find these genetic markers. The goal is to better understand why some patients respond differently to the same treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medicine Invention Design, Inc. - IORG0007849 - NPI 1023387701
Rockville, Maryland, 20853, United States
-
Omnicure Clinical Research
Doral, Florida, 33172, United States
Conditions
Explore the condition pages connected to this study.